



Nexstim Plc
(“Nexstim” or the “Company”)

The decisions of the Board of Directors

Helsinki, 31th March 2015 at 15.00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that the Board of Directors of Nexstim Plc. has today, in the meeting that took place after the Annual General Meeting, elected the members of the Board Committees as follows:

The chairman of the Audit Committee shall be Juliet Thompson and the members shall be Juha Vapaavuori and Ekaterina Smirnyagina.

The chairman of the Compensation committee shall be Ken Charhut and the members shall be Johan Christenson and Olli Riikkala.

For the time being, the following members shall continue in the Nomination Committee: the chairman shall be Staffan Lindstrand and the members shall be Sami Tuhkanen and Jos Peeters. The Board Chairman, Olli Riikkala, shall participate in the Nomination Committee meetings.

The following members of the Board of Directors of Nexstim Plc: Johan Christenson, Rene Kuijten, Ekaterina Smirnyagina and Juha Vapaavuori and the members of the Nomination Committee: Staffan Lindstrand, Sami Tuhkanen and Jos Peeters have announced that they will not be accepting Board fees from the Company. The above mentioned Board members will be receiving travelling reimbursements according to the decision of the Annual General Meeting.

NEXSTIM PLC

Janne Huhtala, Chief Executive Officer

For further information please visit www.nexstim.com or contact:

Nexstim

Janne Huhtala, Chief Executive Officer

+358 (0)40 8615046

janne.huhtala@nexstim.com

UB Capital Oy (Certified Adviser)

+358 (0)9 2538 0225

Consilium Strategic Communications

Mary-Jane Elliott / Ivar Milligan

+44 (0)20 3709 5700

nexstim@consilium-comms.com

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke



therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.